Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement. Death due to respiratory failure occurs typically 2–5 years after disease onset (Suzuki et al., ). Our basic and clinical studies have proven that OECs have neuroprotective effect and can improve quality of life and prolong surviving time (Huang et al., , ; Chen et al., , ; Li et al., ). Dr. Piepers (Piepers and van den Berg, ) published a paper to make comment on our work, in which there were some wrong viewpoints and errors. Also there may be someone sharing same viewpoints with his paper. In order to avoid misleading readers, it is our irresistible duty to tell people the truth what happened about treatment study, show more evidences, and facts of development for this disease. Herein, we encourage people to read his original paper with our thoughts in mind. We strongly believe that scientific truth should rely on facts, but not conjecture.
“These Therapies Aim at Neuronal Replacement or Use Embryonic or Neuronal Stem Cells to Prevent Dysfunctional Motor Neurons From Dying” is Correct?
In fact, the mechanisms for neurorestoration in ALS are very complex, which lie on neural regeneration, repair, and replacement of damaged components of the nervous system, neuroplasticity, neuroprotection and neuromodulation, vasculogenesis, and recovery mechanisms of immune regulation (Fornai et al., ; IANR, ; Mitrecić et al., ; Huang et al., ). Embryonic or neuronal stem cells hardly replace motor neuron in ALS and also are difficult to have useful functions as people expect. Otherwise, transplanted cells can serve as a source of trophic factors providing neuroprotection, slowing down neuronal degeneration, and disease progression. Presently, cell–based neurorestorative treatment has become a new trend (Huang, ). Rapidly increasing worldwide data have proven that it has a pivotal therapeutic value in ALS (see Tables 1 and 2; Chen et al., ). So neruoprotection is one of the most functional neurorestorative strategies for ALS; unfortunately Dr. Piepers fully ignored most of the progress in this research field.
Table 1
| Authors | Country | Year | Publications |
|---|---|---|---|
| Demierre et al. () | Switzerland | Demierre et al. () | Grafting of embryonic motoneurons into adult spinal cord and brain |
| Clowry et al. () | UK | Clowry et al. () | Transplants of embryonic motoneurones to adult spinal cord: survival and innervation abilities |
| Sagot et al. () | Switzerland | Sagot et al. () | Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor (CNTF) can slow down progressive motor neuronopathy in the mouse |
| Cooper et al. () | France | Cooper et al. () | Intraspinal injection of embryonic neurons maintains muscle phenotype in adult chronic spinal rats |
| Mohajeri et al. () | USA | Mohajeri et al. () | Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in familial ALS mice |
| Ende et al. () | USA | Ende et al. () | Human umbilical cord blood effect on SOD mice (plus 800 cGy of irradiation) |
| Garbuzova-Davis et al. () | USA | Garbuzova-Davis et al. () | Positive effect of transplantation of hNT neurons (NTera 2/D1 cell line) in a model of familial ALS |
| Kerr et al. () | USA | Kerr et al. () | Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury |
| Garbuzova-Davis et al. () | USA | Garbuzova-Davis et al. () | Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation |
| Corti et al. () | Italy | Corti et al. () | Wild-type bone marrow cells ameliorate the phenotype of SOD1–G93A mice and contribute to CNS, heart, and skeletal muscle tissues |
| Gao et al. () | USA | Gao et al. () | Human neural stem cell-derived cholinergic neurons innervate muscle in motoneuron deficient adult rats |
| Li et al. () | USA | Li et al. () | Fate of immortalized human neuronal progenitor cells transplanted in rat spinal cord |
| Klein et al. () | USA | Klein et al. () | GDNF delivery using human neural progenitor cells in a rat model of ALS |
| Hemendinger et al. () | USA | Hemendinger et al. () | Sertoli cells improve survival of motor neurons in SOD1 transgenic mice |
| Corti et al. () | Italy | Corti et al. () | Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1 |
| Solomon et al. () | Canada | Solomon et al. () | Origin and distribution of bone marrow-derived cells in the central nervous system in ALS mice |
| Yan et al. () | USA | Yan et al. () | Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in ALS transgenic mice |
| Salah-Mohellibi et al. () | France | Salah-Mohellibi et al. () | Bone marrow transplantation attenuates the myopathic phenotype of a muscular mouse model of spinal muscular atrophy |
| Huang et al. () | China | Huang et al. () | Effect of transplantation of wild-type bone marrow stem cells in familial ALS mice |
| Xu et al. () | USA | Xu et al. () | Human neural stem cell grafts ameliorate motor neuron disease in SOD1 transgenic rats |
| Lim et al. () | Australia | Lim et al. () | Derivation of motor neurons from three clonal human embryonic stem cell lines |
| Suzuki et al. () | USA | Suzuki et al. () | GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS |
| Zhao et al. () | China | Zhao et al. () | Human mesenchymal stromal cells ameliorate the phenotype of SOD1–G93A ALS mice |
| Christou et al. () | UK | Christou et al. () | Embryonic stem cells and prospects for their use in regenerative medicine approaches to motor neuron disease |
| Martin and Liu () | USA | Martin and Liu () | Adult olfactory bulb neural precursor cell grafts provide temporary protection from motor neuron degeneration, improve motor function, and extend survival in ALS mice |
| Kang and Rivest () | Canada | Kang and Rivest () | MyD88-deficient bone marrow cells accelerate onset and reduce survival in ALS mice |
| Garbuzova-Davis et al. () | USA | Garbuzova-Davis et al. () | Human umbilical cord blood treatment in ALS mice: optimization of cell dose |
| Vercelli et al. () | Italy | Vercelli et al. () | Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in ALS mice |
| Suzuki et al. () | USA | Suzuki et al. () | Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in familial ALS rats |
| Beers et al. () | USA | Beers et al. () | CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS |
| Lepore et al. () | USA | Lepore et al. () | Focal transplantation-based astrocyte replacement is neuroprotective in ALS. [lineage-restricted astrocyte precursors, glial-restricted precursors (GRPs)] |
| Xu et al. () | USA | Xu et al. () | Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry |
| Zhang et al. () | China | Zhang et al. () | Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in ALS transgenic mice |
| Hwang et al. () | Korea | Hwang et al. () | Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay, and survival extension in transgenic ALS mice |
| López-González et al. () | México | López-González et al. () | Transient recovery in familial ALS rats after transplantation of motor neurons derived from mouse embryonic stem cells |
| Kim et al. () | Korea | Kim et al. () | Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1–G93A ALS mice |
| Guo et al. () | USA | Guo et al. () | Characterization of a human fetal spinal cord stem cell line, NSI-566RSC, and its induction to functional motoneurons |
| Gu et al. () | China | Gu et al. () | Human adipose-derived stem cells enhance the glutamate uptake function of GLT1 in SOD1(G93A)-bearing astrocytes |
| Mitrecić et al. () | Belgium | Mitrecić et al. () | Distribution, differentiation, and survival of intravenously administered neural stem cells in a rat model of amyotrophic lateral sclerosis |
| Rizvanov et al. () | Russia | Rizvanov et al. () | Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice |
| Xu et al. () | USA | Xu et al. () | Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats |
| Forostyak et al. () | Czech | Forostyak et al. () | Mesenchymal stromal cells prolong the lifespan in a rat model of ALS |
| Pastor et al. () | Spain | Pastor et al. () | Comparative effects between bone marrow and mesenchymal stem cell transplantation in GDNF expression and motor function recovery in ALS mouse |
| Lunn et al. () | USA | Lunn et al. () | Stem cell technology for motor neuron diseases |
| Sanberg et al. () | USA | Sanberg et al. () | Treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells |
Selected preclinical literatures of cell-based therapy for ALS (data from Pubmed; modified from 5).
Table 2
| Authors | Country | Year | Publications |
|---|---|---|---|
| Aebischer et al. () | Switzerland | Aebischer et al. () | Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in ALS patients |
| Mazzini et al. () | Italy | Mazzini et al. () | Stem cell therapy in ALS: a methodological approach in humans (BMSCs) |
| Huang et al. () | China | Huang et al. () | MR spectroscopy evaluation and short-term outcome of OEC transplantation in ALS patients |
| Chen et al. () | China | Chen et al. () | Short-term outcome of OEC transplantation for ALS |
| Huang et al. () | China | Huang et al. () | Fetal OEC transplantation in ALS patients: a controlled study |
| Badayan and Cudkowicz () | USA | Badayan and Cudkowicz () | Mesenchymal stem cell trials in people with ALS |
| Cashman et al. () | Canada | Cashman et al. () | Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in ALS |
| Deda et al. () | Turkey | Deda et al. () | Treatment of ALS patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up |
| Martinez et al. () | Mexico | Martinez et al. () | Stem cell transplantation into the frontal motor cortex in ALS patients. Cytotherapy. [CD133(+) cells] |
| Choi et al. () | Korea | Choi et al. () | Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis |
| Karussis et al. () | Israel | Karussis et al. () | Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis |
Literatures of cell-based therapy in ALS humans (data from Pubmed; modified from 5).
What Ideal Expectation of Treatment is and What Current Medicine Can Do for ALS?
To attenuate the rate of deterioration should be considered and encouraged as the main aim at the current time, because the cure has not yet been made available so far. So any improvement is very important for patients with ALS. Based on Dr. Piepers’ paper, we at least found three out of a total of seven patients who had reversed their functions after our treatment. Our recent study, multiple transplantations for ALS shows that every single treatment could make functional improvement for patients (Table 3; Chen et al., ). These essential findings should be translated as highlighted positive results because specialists in the ALS study community around the whole world know there is no way to reverse the clinical course of ALS through routine treatment including Rilutek. People should not require current medicine to get treatment results as their ideal expectation for some untreatable diseases such as ALS.
Table 3
| Cell transplant | ALS–FRS | Norris scale | ||||
|---|---|---|---|---|---|---|
| Pre-treatment | Post-treatment | Increased score | Pre-treatment | Post-treatment | Increased score | |
| 1st | 24.5 ± 7.1 | 27.1 ± 7.1 | 2.6 ± 2.4 | 55.9 ± 20.9 | 60.8 ± 22.1 | 4.9 ± 5.2 |
| 2nd | 20.1 ± 7.3 | 21.1 ± 7.4 | 1.1 ± 1.3 | 43.0 ± 21.6 | 45.6 ± 21.8 | 2.3 ± 0.2.9 |
| 3rd | 18.3 ± 7.7 | 19.4 ± 8.4 | 1.1 ± 1.5 | 36.1 ± 20.9 | 39.6 ± 23.1 | 3.4 ± 0.6.9 |
| 4th | 20.5 ± 4.9 | 20.5 ± 4.9 | 0.0 ± 0.0 | 37.5 ± 24.7 | 40.05 ± 28.3 | 2.5 ± 0.3.5 |
Amyotrophic lateral sclerosis–FRS and Norris scale score and increased score after four treatments.
There was statistic difference between pre-treatment ALS–FRS and Norris scale score and post-treatment score after 1st and 2nd cell therapy (p < 0.01). Increased scores of ALS–FRS in 1st group was significantly more than the other 3 groups (p < 0.05) and no statistic differences were shown between 2nd and 3rd, 3rd and 4th group (p > 0.05), but it is difference between 2nd and 4th (p < 0.05). There was statistic difference on increased score of Norris scale between 1st and 2nd cell transplant (p = 0.019).
Where should the Cells be Transplanted into?
We can understand why Dr. Piepers said that “it is difficult to understand how focal injection of OECs into the corona radiata of ALS patients would result in improved function of motor neurons that are not in close proximity to the injection site.” We compared two ways by transplanting cells into spinal cord or brain; and there was no difference of functional improvement between two methods (Chen et al., ). We are also doing experimental study which will be published soon. People will know more about the progress in this field from our current experimental study, that is, OEC transplantation in corona radiate prolongs the survival of SOD1–G93A rats with protection to not only the upper motor neurons but lower motor neurons in cornu anterius medullae spinalis as well.
“It has been Shown that Injecting Stem Cells into the Spinal Cord of ALS Patients is Technically Feasible and Safe” is Correct?
It is well known that the spinal cord surgery under the general anesthesia has more risks in ALS patients, so we have improved our treatment from the initial intraspinal cord transplantation since over 5 years ago. Our clinical study proved that local anesthesia and stereotactic procedure has much less body damage for ALS patients than general anesthesia and open spinal surgery (Chen et al., ). We suggest that Dr. Piepers should do more clinical investigations or get clinical experience before he comments or discusses on which method is better, feasible, and safe for clinical issue.
Immunosuppressant is Necessary?
The application of immunosuppressant remains controversial after cell transplantation into the brain and/or spinal cord. In additional, some of the ALS patients are too weak to tolerate the drugs. Most recently, OECs were able to stay alive for at least 12–24 months which has been proven through two autopsies by Italian physicians (Giordana et al., ).
In summary, to talk by conjecture is a simple process; however, to really help patients with ALS to improve their neurological functions and quality of life must face hardships and challenges. The community should encourage any efforts to discover effective therapeutic strategies globally. Fortunately, now clinical studies already showed that cell therapy could restore patients’ neurological functions by neuroprotection or some other mechanisms.
References
1
AebischerP.SchluepM.DéglonN.JosephJ. M.HirtL.HeydB.GoddardM.HammangJ. P.ZurnA. D.KatoA. C.RegliF.BaetgeE. E. (1996). Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med.2, 696–699.10.1038/nm0696-696
2
BadayanI.CudkowiczM. E. (2008). Is it too soon for mesenchymal stem cell trials in people with ALS?Amyotroph.Lateral Scler.9, 321–322.10.1080/17482960802425559
3
BeersD. R.HenkelJ. S.ZhaoW.WangJ.AppelS. H. (2008). CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U.S.A.105, 15558–15563.10.1073/pnas.0807419105
4
CashmanN.TanL. Y.KriegerC.MädlerB.MackayA.MackenzieI.BennyB.NantelS.FabrosM.ShinobuL.YousefiM.EisenA. (2008). Pilot study of granulocyte colony stimulating factor (G–CSF)–mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve37, 620–625.10.1002/mus.20951
5
ChenL.ChenD.XiH.WangQ.LiuY.ZhangF.WangH.RenY.XiaoJ.WangY.HuangH. (2012). Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients, benefits from multiple transplantations. Cell Transplant.20. (in press).
6
ChenL.HuangH.ZhangJ.ZhangF.LiuY.XiH.WangH.GuZ.SongY.LiY.TanK. (2007). Short–term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi21, 961–966.
7
ChoiM. R.KimH. Y.ParkJ. Y.LeeT. Y.BaikC. S.ChaiY. G.JungK. H.ParkK. S.RohW.KimK. S.KimS. H. (2010). Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci. Lett.472, 94–98.10.1016/j.neulet.2010.01.054
8
ChristouY. A.MooreH. D.ShawP. J.MonkP. N. (2007). Embryonic stem cells and prospects for their use in regenerative medicine approaches to motor neurone disease. Neuropathol. Appl. Neurobiol.33, 485–498.10.1111/j.1365-2990.2007.00883.x
9
ClowryG.SieradzanK.VrbováG. (1991). Transplants of embryonic motoneurones to adult spinal cord, survival and innervation abilities. Trends Neurosci.14, 355–357.10.1016/0166-2236(91)90162-N
10
CooperR. N.Feraboli–LohnherrD.Butler–BrowneG.OrsalD.GimenezY.RibottaM.PrivatA. (1996). Intraspinal injection of embryonic neurons maintains muscle phenotype in adult chronic spinal rats. J. Neurosci. Res.46, 324–329.10.1002/(SICI)1097-4547(19961101)46:3<324::AID-JNR5>3.0.CO;2-M
11
CortiS.LocatelliF.DonadoniC.GuglieriM.PapadimitriouD.StrazzerS.Del BoR.ComiG. P. (2004). Wild–type bone marrow cells ameliorate the phenotype of SOD1–G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain127, 2518–2532.10.1093/brain/awh273
12
CortiS.LocatelliF.PapadimitriouD.DonadoniC.Del BoR.CrimiM.BordoniA.FortunatoF.StrazzerS.MenozziG.SalaniS.BresolinN.ComiG. P. (2006). Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of NMD mice, an animal model of SMARD1. Hum. Mol. Genet.15, 167–187.10.1093/hmg/ddi446
13
DedaH.InciM. C.KürekçiA. E.SavA.KayihanK.OzgünE.UstünsoyG. E.KocabayS. (2009). Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow–derived hematopoietic stem cell transplantation, a 1–year follow–up. Cytotherapy11, 18–25.10.1080/14653240802549470
14
DemierreB.Ruiz–FlandesP.MartinouJ. C.KatoA. C. (1990). Grafting of embryonic motoneurons into adult spinal cord and brain. Prog. Brain Res.82, 233–237.10.1016/S0079-6123(08)62609-6
15
EndeN.WeinsteinF.ChenR.EndeM. (2000). Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sci.67, 53–59.10.1016/S0024-3205(00)00602-0
16
FornaiF.LongoneP.CafaroL.KastsiuchenkaO.FerrucciM.MancaM. L.LazzeriG.SpalloniA.BellioN.LenziP.ModugnoN.SicilianoG.IsidoroC.MurriL.RuggieriS.PaparelliA. (2008). Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A.105, 2052–2057.10.1073/pnas.0708022105
17
ForostyakS.JendelovaP.KapcalovaM.ArboledaD.SykovaE. (2011). Mesenchymal stromal cells prolong the lifespan in a rat model of amyotrophic lateral sclerosis. Cytotherapy13, 1036–1046.10.3109/14653249.2011.592521
18
GaoJ.CoggeshallR. E.TarasenkoY. I.WuP. (2005). Human neural stem cell–derived cholinergic neurons innervate muscle in motoneuron deficient adult rats. Neuroscience131, 257–262.10.1016/j.neuroscience.2004.10.033
19
Garbuzova-DavisS.SanbergC. D.Kuzmin-NicholsN.WillingA. E.GemmaC.BickfordP. C.MillerC.RossiR.SanbergP. R. (2008). Human umbilical cord blood treatment in a mouse model of ALS, optimization of cell dose. PLoS ONE3, e2494.10.1371/journal.pone.0002494
20
Garbuzova-DavisS.WillingA. E.MillikenM.SaportaS.ZigovaT.CahillD. W.SanbergP. R. (2002). Positive effect of transplantation of hNT neurons (NTera 2/D1 cell–line) in a model of familial amyotrophic lateral sclerosis. Exp. Neurol.174, 169–180.10.1006/exnr.2002.7860
21
Garbuzova-DavisS.WillingA. E.ZigovaT.SaportaS.JustenE. B.LaneJ. C.HudsonJ. E.ChenN.DavisC. D.SanbergP. R. (2003). Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis, distribution, migration, and differentiation. J. Hematother. Stem Cell Res.12, 255–270.10.1089/152581603322022990
22
GiordanaM. T.GrifoniS.VottaB.MagistrelloM.VercellinoM.PellerinoA.NavoneR.ValentiniC.CalvoA.ChiòA. (2010). Neuropathology of olfactory ensheathing cell transplantation into the brain of two amyotrophic lateral sclerosis (ALS) patients. Brain Pathol.20, 730–737.10.1111/j.1750-3639.2009.00353.x
23
GuR.HouX.PangR.LiL.ChenF.GengJ.XuY.ZhangC. (2010). Human adipose–derived stem cells enhance the glutamate uptake function of GLT1 in SOD1(G93A)–bearing astrocytes. Biochem. Biophys. Res. Commun.393, 481–486.10.1016/j.bbrc.2010.02.029
24
GuoX.JoheK.MolnarP.DavisH.HickmanJ. (2010). Characterization of a human fetal spinal cord stem cell line, NSI–566RSC, and its induction to functional motoneurons. J. Tissue Eng. Regen. Med.4, 181–193.10.1002/term.223
25
HemendingerR.WangJ.MalikS.PersinskiR.CopelandJ.EmerichD.GoresP.HalberstadtC.RosenfeldJ. (2005). Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosis. Exp. Neurol.196, 235–243.10.1016/j.expneurol.2005.07.025
26
HuangH. (2010). Neurorestoratology, a distinct discipline and a new era: a brief introduction to the first IANR section. Cell Transplant.19, 129–131.10.3727/096368910X492580
27
HuangH.ChenL.SanbergP. (2010). Cell therapy from bench to bedside translation in CNS Neurorestoratology era. Cell Med.1, 15–46.10.3727/215517910X516673
28
HuangH.ChenL.XiH.WangH.ZhangJ.ZhangF.LiuY. (2008). Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients, a controlled pilot study. Clin. Transplant.22, 710–718.10.1111/j.1399-0012.2008.00865.x
29
HuangH.TanK.ChenL.XueY.WangH.XiH.LiuY.ZhangF.ZhangJ. (2007). MR spectroscopy evaluation and short–term outcome of olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi21, 52–57.
30
HuangH.ZhangC.ZhaoC. P.YaoX. L.XiJ. (2006). Effect of transplantation of wild–type bone marrow stem cells in mouse model of familial amyotrophic lateral sclerosis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao28, 562–566.
31
HwangD. H.LeeH. J.ParkI. H.SeokJ. I.KimB. G.JooI. S.KimS. U. (2009). Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther.16, 1234–1244.10.1038/gt.2009.80
32
International Association of Neurorestoratology (IANR). (2009). Beijing declaration of international association of neurorestoratology. Cell Transplant.18, 487.10.3727/096368909788809866
33
KangJ.RivestS. (2007). MyD88–deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. J. Cell Biol.179, 1219–1230.10.1083/jcb.200705046
34
KarussisD.KarageorgiouC.Vaknin-DembinskyA.Gowda-KurkalliB.GomoriJ. M.KassisI.BulteJ. W.PetrouP.Ben-HurT.AbramskyO.SlavinS. (2010). Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol.67, 1187–1194.10.1001/archneurol.2010.248
35
KerrD. A.LladóJ.ShamblottM. J.MaragakisN. J.IraniD. N.CrawfordT. O.KrishnanC.DikeS.GearhartJ. D.RothsteinJ. D. (2003). Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J. Neurosci.23, 5131–5140.
36
KimH. Y.ChoiM. R.HwangS.NamK. H.KimH. C.HanJ. S.KimK. S.YoonH. S.KimS. H. (2010). Dose–dependent efficacy of ALS–human mesenchymal stem cells transplantation into cisterna magna in SOD1–G93A ALS mice. Neurosci. Lett.468, 190–194.10.1016/j.neulet.2009.10.084
37
KleinS. M.BehrstockS.McHughJ.HoffmannK.WallaceK.SuzukiM.AebischerP.SvendsenC. N. (2005). GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther.16, 509–521.10.1089/hum.2005.16.509
38
LeporeA. C.RauckB.DejeaC.PardoA. C.RaoM. S.RothsteinJ. D.MaragakisN. J. (2008). Focal transplantation–based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci.11, 1294–1301.10.1038/nn.2210
39
LiP.TesslerA.HanS. S.FischerI.RaoM. S.SelzerM. E. (2005). Fate of immortalized human neuronal progenitor cells transplanted in rat spinal cord. Arch. Neurol.62, 223–229.10.1001/archneur.62.2.223
40
LiY.BaoJ.KhatibiN. H.ChenL.WangH.DuanY.HuangH.ZhouC. (2011). Olfactory ensheathing cell transplantation into spinal cord prolongs the survival of mutant SOD1(G93A) ALS rats through neuroprotection and remyelination. Anat. Rec. (Hoboken)294, 847–857.10.1002/ar.21362
41
LimU. M.SidhuK. S.TuchB. E. (2006). Derivation of motor neurons from three clonal human embryonic stem cell lines. Curr. Neurovasc. Res.3, 281–288.10.2174/156720206778792902
42
López-GonzálezR.KuncklesP.VelascoI. (2009). Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells. Cell Transplant.18, 1171–1181.10.3727/096368909X12483162197123
43
LunnJ. S.SakowskiS. A.FedericiT.GlassJ. D.BoulisN. M.FeldmanE. L. (2011). Stem cell technology for the study and treatment of motor neuron diseases. Regen. Med.6, 201–213.10.2217/rme.11.6
44
MartinL. J.LiuZ. (2007). Adult olfactory bulb neural precursor cell grafts provide temporary protection from motor neuron degeneration, improve motor function, and extend survival in amyotrophic lateral sclerosis mice. J. Neuropathol. Exp. Neurol.66, 1002–1018.10.1097/01.jnen.0000268900.71988.94
45
MartinezH. R.Gonzalez–GarzaM. T.Moreno–CuevasJ. E.CaroE.Gutierrez–JimenezE.SeguraJ. J. (2009). Stem–cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy11, 26–34.10.1080/14653240802644651
46
MazziniL.FagioliF.BoccalettiR.MareschiK.OliveriG.OlivieriC.PastoreI.MarassoR.MadonE. (2003). Stem cell therapy in amyotrophic lateral sclerosis, a methodological approach in humans. Amyotroph. Lateral Scler. Other Motor Neuron Disord.4, 158–161.10.1080/14660820310014653
47
MitrecićD.GajovićS.PochetR. (2009). Toward the treatments with neural stem cells, experiences from amyotrophic lateral sclerosis. Anat. Rec.292, 1962–1967.10.1002/ar.20971
48
MitrecićD.NicaiseC.GajovićS.PochetR. (2010). Distribution, differentiation, and survival of intravenously administered neural stem cells in a rat model of amyotrophic lateral sclerosis. Cell Transplant.19, 537–548.10.3727/096368910X498269
49
MohajeriM. H.FiglewiczD. A.BohnM. C. (1999). Intramuscular grafts of myoblasts genetically modified to secrete glial cell line–derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum. Gene Ther.10, 1853–1866.10.1089/10430349950017536
50
PastorD.Viso-LeĂłnM. C.JonesJ.Jaramillo-MerchánJ.Toledo-AralJ. J.MoraledaJ. M.MartĂnezS. (2011). Comparative effects between bone marrow and mesenchymal stem cell transplantation in GDNF expression and motor function recovery in a motorneuron degenerative mouse model. Stem Cell. Rev. [Epub ahead of print].
51
PiepersS.van den BergL. H. (2010). No benefits from experimental treatment with olfactory ensheathing cells in patients with ALS. Amyotroph. Lateral Scler.11, 328–330.10.3109/17482961003663555
52
RizvanovA. A.GusevaD. S.SalafutdinovI. I.KudryashovaN.V.BashirovF. V.KiyasovA. P.YalvaçM. E.GazizovI. M.KaliginM. S.SahinF.MukhamedyarovM. A.PalotásA.IslamovR. R. (2011). Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Exp. Biol. Med. (Maywood)236, 91–98.10.1258/ebm.2010.010172
53
SagotY.TanS. A.BaetgeE.SchmalbruchH.KatoA. C.AebischerP. (1995). Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor (CNTF) can slow down progressive motor neuronopathy in the mouse. Eur. J. Neurosci.7, 1313–1322.10.1111/j.1460-9568.1995.tb01122.x
54
Salah-MohellibiN.MilletG.André–SchmutzI.DesforgesB.OlasoR.RoblotN.CourageotS.BensimonG.Cavazzana-CalvoM.MelkiJ. (2006). Bone marrow transplantation attenuates the myopathic phenotype of a muscular mouse model of spinal muscular atrophy. Stem Cells24, 2723–2732.10.1634/stemcells.2006-0170
55
SanbergP. R.EveD. J.WillingA. E.Garbuzova-DavisS.TanJ.SanbergC. D.AllicksonJ. G.CruzL. E.BorlonganC. V. (2011). The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells. Cell Transplant.20, 85–94.10.3727/096368911X593127
56
SolomonJ. N.LewisC. A.AjamiB.CorbelS. Y.RossiF. M.KriegerC. (2006). Origin and distribution of bone marrow–derived cells in the central nervous system in a mouse model of amyotrophic lateral sclerosis. Glia53, 744–753.10.1002/glia.20331
57
SuzukiM.McHughJ.TorkC.ShelleyB.HayesA.BellantuonoI.AebischerP.SvendsenC. N. (2008). Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther.16, 2002–2010.10.1038/mt.2008.159
58
SuzukiM.McHughJ.TorkC.ShelleyB.KleinS. M.AebischerP.SvendsenC. N. (2007). GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE2, e689.10.1371/journal.pone.0000689
59
VercelliA.MereutaO. M.GarbossaD.MuracaG.MareschiK.RustichelliD.FerreroI.MazziniL.MadonE.FagioliF. (2008). Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis.31, 395–405.10.1016/j.nbd.2008.05.016
60
XuL.RyugoD. K.PongstapornT.JoheK.KoliatsosV. E. (2009). Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats, differentiation and structural integration into the segmental motor circuitry. J. Comp. Neurol.514, 297–309.10.1002/cne.22022
61
XuL.ShenP.HazelT.JoheK.KoliatsosV. E. (2011). Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats. Neurosci. Lett.494, 222–226.10.1016/j.neulet.2011.02.076
62
XuL.YanJ.ChenD.WelshA. M.HazelT.JoheK.HatfieldG.KoliatsosV. E. (2006). Human neural stem cell grafts ameliorate motor neuron disease in SOD–1 transgenic rats. Transplantation82, 865–875.10.1097/00007890-200607152-02412
63
YanJ.XuL.WelshA. M.ChenD.HazelT.JoheK.KoliatsosV. E. (2006). Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells24, 1976–1985.10.1634/stemcells.2005-0518
64
ZhangC.ZhouC.TengJ. J.ZhaoR. L.SongY. Q.ZhangC. (2009). Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis. Cytotherapy11, 299–306.10.1080/14653240903051533
65
ZhaoC. P.ZhangC.ZhouS. N.XieY. M.WangY. H.HuangH.ShangY. C.LiW. Y.ZhouC.YuM. J.FengS. W. (2007). Human mesenchymal stromal cells ameliorate the phenotype of SOD1–G93A ALS mice. Cytotherapy9, 414–426.10.1080/14653240701376413
Summary
Keywords
Amyotrophic lateral sclerosis (ALS), Cell-based neurorestorotherapy
Citation
Chen L, Xi H and Huang H (2011) Cell-Based Neurorestorotherapy in Amyotrophic Lateral Sclerosis – Scientific Truth should Rely on Facts, but Not Conjecture. Front. Integr. Neurosci. 5:83. doi: 10.3389/fnint.2011.00083
Received
04 November 2011
Accepted
29 November 2011
Published
20 December 2011
Volume
5 - 2011
Copyright
© 2011 Chen, Xi and Huang.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
*Correspondence: hongyunh@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.